...
首页> 外文期刊>Radiotherapy and oncology: Journal of the European Society for Therapeutic Radiology and Oncology >Hypofractionated, palliative radiotherapy for advanced head and neck cancer.
【24h】

Hypofractionated, palliative radiotherapy for advanced head and neck cancer.

机译:超分割,姑息性放疗用于晚期头颈癌。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: A significant proportion of advanced stage head and neck cancer patients are incurable and have a limited life expectancy. This study reports a single institution experience with a hypofractionated radiotherapy regimen for palliation of loco-regionally advanced and incurable HNSCC. MATERIALS AND METHODS: Between 2000 and 2005, 110 patients of unresectable HNSCC were treated with a palliative radiotherapy (40Gy in 16 fractions). Distressing symptoms were assessed before treatment. Patients with good objective regression with acceptable toxicity received further escalation of dose till 50Gy. We made three strata to compare symptomatic improvement namely percentage relief <50%, between 50-75% and >75% as compared to baseline. RESULTS: Most common baseline distressing complaints were pain in 109 (99%) patients and dysphagia in 97 (88%) patients. Eleven patients (10%) had complete response (CR) and 80 (73%) patients had complete and partial response (PR). At completion of radiotherapy 26%, 57%, and 17% of patients had <50%, 50-75%, and >75% symptomatic relief, respectively. The overall PFS (defined as either complete disappearance of the disease or non-progression in the irradiated field) at 12 months was 55.1% (95% CI, 40.3%-69.9%). On multivariate analysis weight >50kg (p=0.049) and radiotherapy dose of more than 40Gy (p=0.012) were found to be significant for PFS. Acute and late reactions were acceptable. CONCLUSIONS: The hypofractionated radiotherapy regimen evaluated is an effective treatment modality for sustained symptoms relief with good response rates and acceptable toxicity.
机译:背景:相当大比例的晚期头颈癌患者是无法治愈的,并且预期寿命有限。这项研究报告了单一机构采用局部放疗方案缓解局部区域晚期和无法治愈的HNSCC的经验。材料与方法:在2000年至2005年间,对110例不可切除的HNSCC患者进行了姑息放疗(40Gy分16次)。治疗前评估令人痛苦的症状。客观可接受性良好且毒性可接受的患者,其剂量应进一步提高至50Gy。我们进行了三个阶段的比较,以比较症状改善的情况,即缓解率<50%,与基线相比缓解率在50-75%至> 75%。结果:最常见的基线困扰症状是109例患者(99%)疼痛和吞咽困难97例(88%)患者。 11名患者(10%)有完全缓解(CR),80名患者(73%)有完全和部分缓解(PR)。放疗完成后,分别有26%,57%和17%的患者症状缓解<50%,50-75%和> 75%。 12个月时的总PFS(定义为疾病完全消失或在照射野中未进展)为55.1%(95%CI,40.3%-69.9%)。经多变量分析,体重> 50kg(p = 0.049)和放疗剂量大于40Gy(p = 0.012)对PFS有意义。急性和晚期反应都是可以接受的。结论:所评估的超分割放疗方案是一种有效的治疗方法,可缓解症状,并具有良好的缓解率和可接受的毒性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号